Abstract:Background: Pneumococcal conjugate vaccines (PCVs) in the past, have been constructed via chemical coupling of pneumococcal capsules to immunogenic carrier proteins. The PCVs implementation in developing countries was prevented by their high manufacturing costs. This issue can be overcome via the development of protein-based vaccines against pneumococci. Choline binding protein D (CBPD), fibronectin binding protein (FBP), and D-alanyl-D-alanine-carboxy peptidase (DDCP) were already identified as pneumococcal surface proteins able to elicit protection against S. pneumoniae serotype 19F. Methods: As antibody responses are necessary for protection against pneumococci, the aim of this study is, therefore, to design computationally a chimeric pneumococcal vaccine using B-cell epitope regions of CBPD, FBP, and DDCP. These regions were determined using results of Bepipred, BCPreds and CBTope programs. The most probable immunoprotective B-cell epitope region (MIBR) of each protein was identified using VaxiJen. MIBRs were highly conserved in common S. pneumoniae serotypes causing invasive pneumococcal disease worldwide. The conserved MIBRs were joined together using either flexible (Gly4Ser)2 linker or the rigid AspProArgValProSerSer linker to form antigens with molecular weights of 22.53 kDa and 22.74 kDa, respectively. Results and Discussion: The codon optimization was done for the chimeric antigens. Analysis of mRNAs secondary structures revealed no stable hairpins at 5' ends that could interfere with antigen expression. The 3D model of the antigen possessing the flexible linker contained alpha helix, whereas several beta sheets were observed in the tertiary structure of the antigen possessing the rigid linker and it did not have any alpha helixes. Moreover, the antigen-containing the rigid linker included a beta sheet in the C-terminus of DDCP MIBR, which showed 60% residue identity to the beta sheet in the same region of the partial structure of DDCP obtained from protein data bank. However, the other antigen did not contain any similar structural elements in DDCP MIBR. Conclusion: In silico analyses of physicochemical properties indicated that inclusion of the rigid linker instead of the flexible linker resulted in better stability of the chimeric antigen. In addition, using the rigid linker increased the probability of the protein soluble expression in Escherichia coli. Therefore, the chimeric antigen composed of conserved MIBRs joining via the rigid linker is predicted to be a suitable vaccine candidate, which could elicit protection against common pneumococcal serotypes.

Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae

Preparation and preclinical evaluation of two novel Staphylococcus aureus capsular polysaccharide 5 and 8‐fusion protein (Hla‐MntC‐SACOL0723) immunoconjugates

Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®

Polysaccharide and conjugate vaccines to Streptococcus pneumoniae generate distinct humoral responses

The experimental research of tne preparation for pneumococcal conjugate vaccine using pneumolysin as a protein carrier and its immumogenicity in mice

Evaluation of various adjuvant nanoparticulate formulations for meningococcal capsular polysaccharide-based vaccine

Conjugate of Structurally Reassigned Pneumococcal Serotype 31 Polysaccharide with CRM197 Elicited Potent Immune Response

Development of an Efficacious, Semisynthetic Glycoconjugate Vaccine Candidate against Streptococcus pneumoniae Serotype 1

Preparation and Characterization of a Staphylococcus aureus Capsular Polysaccharide-Protein Conjugate Prepared by a Low Cost Technique: a Proof-of-Concept Study

Synthesis of propargyl glycosides of Streptococcus pneumoniae serotypes 6A and 6B for glycoconjugate vaccines

A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles

In silico Design of a Novel Serotype Independent Vaccine Against Streptococcus pneumoniae Based on B-cell Epitope Regions of Fibronectin Binding Protein, Choline Binding Protein D, and D-alanyl-D-alanine Carboxypeptidase

Studies on Vaccine Control and Immunogenicity of Polysaccharides of Streptococcus pneumoniae

Effect of individual conjugate dose on immunogenicity of type 6B pneumococcal polysaccharide-N. meningitidis outer membrane protein complex conjugate vaccines in infant rhesus monkeys

A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host

Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine

Synthesis and Immunogenicity Evaluation of Oligosaccharide Epitopes for the Development of Glycoconjugate Vaccine against Streptococcus pneumoniae Serotype 3

Evaluation of the immunogenicity and efficacy of a Hib polysaccharide-protein conjugate vaccine by using PsaA as carrier protein

Conjugation of Multiple Proteins Onto the Surface of PLGA/Lipid Hybrid Nanoparticles

Development and Immunogenicity of a Prototype Multivalent Group B Streptococcus Bioconjugate Vaccine